Abstract
Moxalactam is a new β-lactam antibiotic with a long half-life and broad in-vitro activity against many aerobic and anaerobic Gram-negative bacilli including Pseudomonas aeruginosa and Bacteroides fragilis. We evaluated moxalactam clinically in 53 infected patients with significant underlying diseases. Forty-three patients (81%) responded favourably to moxalactam therapy, including fourteen with infections caused by Ps. aeruginosa. Mild side effects (skin rash, diarrhoea, and hepatic transaminase elevation) occurred in six patients. Two patients developed fungemia and one developed mild elevation of serum creatinine attributed to moxalactam which resolved after discontinuation of therapy. Seven patients with pretreatment renal dysfunction demonstrated improvement in serum creatinine while receiving moxalactam. Three organisms developed resistance during therapy. Treatment failures occurred more commonly in patients with infections due to Ps. aeruginosa with an MIC > 16 mg/l and with infections due to Gram-positive cocci. In summary, moxalactam is effective therapy for serious infections caused by susceptible Gram-negative bacilli.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 435-443 |
| Number of pages | 9 |
| Journal | Journal of Antimicrobial Chemotherapy |
| Volume | 10 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 1982 |
Funding
The authors gratefully acknowledge the excellent technical assistance of Ms Rene Magnuson, Ms Nanette Snowden, Mrs Eileen Metzger and Ms Eileen Matthews and the secretarial aid of Ms Yvonne Washington. This study would not have been possible without the cooperation of the resident and attending staff of the participating hospitals. Work was supported in part by the Samual Sackett Endowment for Infectious Diseases and Hypersensitivity and the Eli Lilly Research Corporation.
ASJC Scopus subject areas
- Pharmacology
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)
